Search

Your search keyword '"Soledad Fernandez"' showing total 286 results
Start Over Author "Soledad Fernandez"
286 results on '"Soledad Fernandez"'

1. Ethnic and racial differences in children and young people with respiratory and neurological post-acute sequelae of SARS-CoV-2: an electronic health record-based cohort study from the RECOVER InitiativeResearch in context

Author

Suchitra Rao, Rodrigo Azuero-Dajud, Vitaly Lorman, Jeremy Landeo-Gutierrez, Kyung E. Rhee, Julie Ryu, C. Kim, Megan Carmilani, Rachel S. Gross, Sindhu Mohandas, Srinivasan Suresh, L. Charles Bailey, Victor Castro, Yalini Senathirajah, Shari Esquenazi-Karonika, Shawn Murphy, Steve Caddle, Lawrence C. Kleinman, Leah Castro-Baucom, Carlos R. Oliveira, Jonathan D. Klein, Alicia Chung, Lindsay G. Cowell, Charisse Madlock-Brown, Carol Reynolds Geary, Marion R. Sills, Lorna E. Thorpe, Jacqueline Szmuszkovicz, Kelan G. Tantisira, Ivan Diaz, Rachel Kenny, Parsa Mirhaji, Ravi Jhaveri, Marc Rosenman, Christopher Forrest, Beth Tarini, Hiroki Morizono, Nathan Pajor, W. Schuyler Jones, Kieler Curtis, Rishi Kamaleswaran, Nita Deshpande, Saul Blecker, Claudia Pulgarin, Marion Sills, Erin Hinkman, Dan Fort, Timothy Guthrie, Cynthia Chuang, Wenke Hwang, Dimitri Christakis, Daksha Ranade, Shannon Herring, Aaron Mishkin, Soledad Fernandez, Neena Thomas, Yuriy Bisyuk, Jyotsna Fuloria, Elizabeth Chrischilles, Boyd Knosp, Asa Oxner, Athanasios Tsalatsanis, Lindsay Cowell, Phillip Reeder, Stephen M. Downs, Brian Ostasiewski, Rainu Kaushal, Thomas Campion, Jessica Snowden, Katherine Irby, Paul Darden, Lexie Dixon, Danielle Evans, Connor Garbe, Laura Hobart-Porter, Lee Howard, Kathy Hummel, Hannah Krehbiel, Haley Spradlin, Phaedra Yount, Amy Elliott, Grace Adam, Jyoti Angal, Maria Barber, Katelynne Clark, Clayton Dos Reis, Mandy Freesemann, Christa Friedrich, Christine Hockett, Rachel Johannsen, Emily Johnson-Vonk, Cassidy Kaiser, Alexa Kruse, Jennifer Lang, Peter Lim, Meggie McCoy, Lorie Miller, Shelby Petereit (Cerkovnik), Jaime RiChard (Werpy), Jessica Seiler, Bret Sundleaf, Joshua Svendsen, Billy Trosper, Olivia Vermeulen, Scott Young, Aul Palumbo, Sean Dabney, Marie-Christine Fahrner, Torrey Gallagher, Karilyn Martini, Mary McNally, Sarah Vivensi Stiverson, Jessica Kosut, Venkataraman Balaraman, JoAnn Cheung, Travis K.F. Hong, Shanelle Kalua, Evan Minami, Andrea Siu, Micah Tong, Ronald J. Teufel, II, Andy Atz, Marina Dantas, Tyler Kasmarcak, Kreighton Milks, Judith Ross, Chijoke Ikomi, Marisa Meyer, Connie Nguyen, Gwen Pellicciotti, Thao-Ly Phan, Karen Ravin, Victoria Reynolds, Abigail Strang, Deepika Thacker, Dan Eckrich, Annabelle Goetter, Cheyenne Katz, Karen Kowal, Carol McDevitt, Emily Zimmerman, Genesis Agosto Roman, Akram Alshawabkeh, Ishwara Ayala Ortiz, Virginia Casey, Jose Cordero, Jocelyn De Jesus, Crystal Galan, Gredia Huerta-Montanez, Nilda Otero, Mayra Rivera Robles, Priscilla Roman, Genesis Roman, Zaira Rosario-Pabon, Xiodenis Santiago, Carmen Velez-Vega, Carlos Vergara, Daniel S. Hsia, Baylea Albarado, Tracey Allen, Allison Attuso, Taylor Ayers, Emily Bebler, Grace Bella, Alexa Bennett, John Brown, Alison Carville, Sydnie Darby, Kara Devall, Amber Dragg, Angela Elderedge, Elisabeth Fontenot, Greta Fry, Bethany Gildersleeve, Sara Goff, Lauren Harrington, Lisa Jones, Victoria Kaiser, Yejee Lee, Stephen Lee, Erin LeJeune, Robert Leonhard, Jennifer Levatino, Donald Lewis, Angrielle Lloyd, Ron Monce, Susannah Munro, Meghan Phillips, Blair Pucheu, Emily Rachal, Jennifer Rood, Stacey Roussel, Renee Rumsey, Connor Sanford, Monica Santos, Aryelle Stafford, Amy Thomassie, Celeste Waguespack, Katherine Walgamotte, Meredith Welch, Aubrey Windham, Michelle Stevenson, Tiffany Bell, Jackie Boyd, Soham Dasgupta, Sarah Deans, Katie Harris, Molly Hemmerle, Sarah King, Cameo McGuire, Brie Merten, Sarah Morris, Madison Ray, Brooklyn Reinhardt, Shellese Shemwell, Theresa Simeon, Katherine Walker, Sara Watson, Kathryn Weakley, Russell McCulloh, Johnathon Figliomeni, Laura Fischer, Denise Hoover, Megan Morse, Aleisha Nabower, Evan Roberts, Alice Sato, Joann Von Bon, Hengameh Raissy, David Archuleta, Rebecca Brito, Richard Campbell, Jude Chavez, Walter Dehority, Noella Garcia-Soberanez, Eve Gronert, Matthew Kadish, Jerry Larrabee, Debbie Lovato, Karen Luo, Noah Martinez, Analyse Merlino, Emily Reese, Sarah Ward, Kevin Wilson, Amanda Bogie, Ryan Brown, Ryan Butchee, Gina Fergeson, Ryan McKee, Brandon Mohler, Tiffany Moore, Valorie Owens, Sarah Stubbs, Timothy Van Wagoner, Kelly Cowan, Meghan Bethel, Laurie Chassereau, Thomas Lahiri, Lesley Cottrell, Lauren Lake, Kathy Moffett, Emily Polak, Sarah Stutler, Charlotte Workman, David Warburton, John C. Wood, Emma Carpenter, Isabelle Dhindsa, Samantha Mejia, Nelly Moghadam, Candice Mulder, Sharon O'Neil, Alisha Osornio, Adrian Rios, Sydney Rosen, Andrea Smith, Deeba Tabibi, Sharon Tang, Ariana Teame, Melissa Stockwell, Joshua Milner, Erika B. Rosenzweig, Brett Anderson, Tawanda Aquino, Elizabeth Berg, Marina Catallozzi, Wendy Chung, Tom Connors, Aliva De, Anny Diaz Perez, Michael DiLorenzo, Dani Dumitriu, Kanwal Farooqi, Michael Fremed, Sylvie Goldman, Kayla Kaplan, Usha Krishnan, Aimee Layton, Angela Lignelli-Dipple, Son McClaren, Jonathan Overdevest, Michelle Rodriguez, Jay Selman, Wendy Silver, Raul Silverio, Ana Valdez de Romero, Celibell Vargas, Alan Werzberger, Daniella Caputo, Camille Leggieri, Pamela Pretsch, Lawrence Kleinman, Sunanda Gaur, Lisa Cerracchio, Amber Folnagy, Maria Gennaro, Sherri Gzemski, Yue Hao, Simon Li, Sandee Moroso, Manette Ness-Cochinwala, Akhil Patel, Benjamin Richlin, Harsh Sharma, Damaris Soto, Christian Suarez, Bibiana Vargas Forero, Lynn Olson, Kristin Davis, Alexander Fiks, Miranda Griffith, Donna Harris, Everly Macario, Jennifer Steffes, Alessandra Torres, Rangaraj Selvarangan, Dithi Banerjee, Chris Day, Kelsye Howell, Megan Mains, Juan C. Salazar, William T. Zempsky, Emily Bean, Carlie DeFelice, Hassan El Chebib, Katherine W. Herbst, Stephanie Lesmes, Ian C. Michelow, Melissa Santos, Noah Schulman, Wilson D. Pace, Alicia Brooks-Greien, Karinne Colin, Christina M. Hester, Ariadna Juarez-Colunga, Brian Manning, Joel Shields, Jack Westfall, Daphne York, Judy Aschner, Katharine Clouser, Justine Griswold, Donna Lee, Amanda Nowakowski, Maryellen Riordan, Hulya Bukulmez, David Kaelber, Rozina Aamir, Mohammed Abuzahrieh, Nandini Bangalore, Alexis Brown, Wendy Dalton, Suzanne Fortuna, Judi Minium, Bonnie Rosolowski, Sheila M. Nolan, Amal Ahmed, Suzanne Braniecki, Montserrat Contreras, Allen Dozor, Supriya Jain, Suzanne Kaseta, Sankaran Krishnan, Zachary Messer, Armando Ramirez, Aalok Singh, Randy Williams, Kyung Rhee, Kelan Tantisira, Almary Akerlundh, Natacha Akshoomoff, Maria Arroyo, Wendy Barrientos, Rakesh Bhattacharjee, Bryant Y. Chao, Maricela Diaz, Sergio Garcia, Sonia Garcia, Guadalupe Gomez, Trinidad Herrera, Margarita Holguin, Manaswitha Khare, Elizabeth Kiernan, Jeremy Landeo Gutierrez, Ileana Matta, Sofia Reyes, Cinthia Sanchez, Andrea Schreck, Megan R. Warner, Uzma Hasan, Elizabeth Ricciardi, Vanessa Trespalacios, Vince Faustino, Matthew Kluko, Bryant Chao, Maria Glenn-Arroyo, Elizabeth A. Kiernan, Anika Madan, Lisa Ramos Vallejo, Cinthia E. Sanchez, Maira Suarez, Patricia Kinser, Amy Salisbury, Jocelyn Espinoza, Sara Moyer, Amy Rider, Sally Russell, Michael Schecter, Lindsey Stevenson, Cheryl R. Stein, Stephanie V. Caldas, Thomas Dylan Castro Ovalle, Anthony Chung, Jonathan S. Farkas, Maria Isidoro-Chino, Deniz Kesebir, Eugenia Kim, Ashley Quarless, Alan Schlechter, Ranjini Srinivasan, Viren D'Sa, Fatoumata Barry, Phoebe Burton, Rosa Cano Lorente, Caroline Cummins, Stephanie Wehbe, Sandra Brown, Anders Dale, Terry Jernigan, Susan Tapert, Jose Aguilar, David Benjamin, Natalie C. Buchbinder, Norma Castro, Brandy Emerson, Hugh Garavan, Jennifer Graves, Amanda Guerrero, Janosch Linkersdoerfer, Robert Schooley, Wes Thompson, Thanh Trinh, Ron Yang, Megan Herting, Elizabeth Sowell, Cynthia Cisneros, Lauren Goedde, Cedric Manlhiot, Raul Gonzalez, Angela Laird, Jorge Limia, Robin Aupperle, Martin Paulus, Melanie Curry, Nour S. El-Sabbagh, Kevin Gray, Lindsay Squeglia, Samuel Agbeh, Cori Herring, Brittany Mckenzie, Bonnie Nagel, Abby Espinoza, Anthony Hill, Angie Morales, Fiona Baker, Eva Muller-Oehring, Ian Colrain, Ingrid Durley, Mirella Dapretto, Lucina Uddin, Susan Bookheimer, Christina Caldera, Jennifer Dzul, Cinthia Zarate, Marie Banich, Paola Badilla, Jennifer Keith, G. Kumar, David Messinger, Katie Prazak, Sara Jo Nixon, Melanie Cardoso, Meagan Sullivan, Stephen Villard, Linda Chang, Thomas Ernst, Christine Cloak, Huajun Liang, Meghann C. Ryan, Mary Heitzerg, Jennifer Conley, Leonard Puttler, Monica Luciana, William Iacono, Aaron Schroeder, Duncan Clark, Doyeon (Dan) Kim, Megan Retucci, Edward Freedman, John Foxe, Sile Ni Mhurchu, Samantha Spallina, Erin McGlade, Deborah Yurgelun-Todd, Liz Bell, Kirsten Cline, Lauren Heinrich, Perry Renshaw, Alexandra Potter, Cass Barrett, Sofia Lozon, Samantha Spear, Christine Larson, Krista Lisdahl, Tory Clearwater, Christine Kaiver, Caitlin Nelson, Zach Paltzer, Bridgette Peteet, James Bjork, Mike Neale, Olive Calonge, Noah Slattery, Lisa Straub, Deanna Barch, Andrew Heath, Pamela Madden, Taylor Powell, Denise Schmitz, Dylan Gee, Boris Epie, Rebekah Hobbs, Alex Williams, Zhouran (Rick) Xiang, Julie Miller, Jane Newburger, Felicia Trachtenberg, Ayesha Amarnath, James Ambrosoli, Denise Artis, Sachin Bandari, Emily Birmingham, Lozan Eyob, Kerri Hayes, Chenwei Hu, Melissa Joyce, Valentina Kazlova, Iris Liu, Amanda Marshall, Devine Mbizdenyuy, P.J. Mu, Robin Rowe, Brooke Sayles, Mo Zhang, Pei-Ni Jone, Michael Carr, Lauren Goodell, Wantanabe Kar, Kathleen Van't Hof, Kristin Sexson, Elias Moussi, David Olukayode, Sandra Pena, Ricardo Pignatelli, Faridis Serrano, Sara Sexson Tejtel, Lara Shekerdemian, Audrey Dionne, Annette Baker, Sarah DeFerrantini, Thomas Giorgio, Numaira Khan, Simran Mahanta, MaryBeth Son, Matt Oster, Melissa Burnett, Kolby Sanders-Lewis, Sonia Chavez, Georgia Reis, Jackie Szmuszkovicz, Fariborz Behzadian, Carla Canas, Andrew Cheng, Mike Gawad, Paige Johnson, Alicia Kazarians, Anastasia Sarkissian, Brandi Scott, Consuelo Secules, Jennifer Su, Crystal Vargas, Jodie Votava-Smith, Sharon Wagner-Lees, Shuo Wang, Pierre Wong, Yamuna Sanil, Sanjeev Aggarwal, Aiman Almasnaah, Nirupama Kannikeswaran, Kathleen Meert, Gautam Singh, Priya Spencer, Nancy Sullivan, Sureja Sundaralingam, Vishnu Undyala, Emily Ward, Amanda Weber, Charmaine Williams Farr, Tamara Bradford, Marla Johnston, Matthew Elias, Alex Fiks, Chris Forrest, Dana Albizem, Susan Coffin, Therese Giglia, Katherine Lupton, Grace Marks, Tonia Morrison, Shawn O'Connor, Daniel Forsha, Jennifer Nelson, Rachel Sachdeva, Dara Watkins, Ashraf S. Harahsheh, Jordyn Britton, Alix Fetch, Anita Krishnan, Onais Tariq, Sean Lang, Marisa Almaguer, Jim Cnota, Lauryn Dugan, Elise Pickering, Kathleen Rathge, Elizabeth Mitchell, Christine Capone, Nilanjana Misra, Olga Shamailova, Mark Russell, Tammy Doman, Lori Harris, Keren Hasbani, Sagar Jani, Brian McCrindle, Jessica Bainton, Maryanne Chrisant, Doris Alaby, Norma Barton, Danielle Katz, Paulette Smith, Stephanie Handler, Joe Block, Regina Cole, Jennifer Maldonado, Kim McHugh, Andrew Atz, Megan Bickford, Jason Buckley, John Costello, Delany Dennis, Elizabeth Emrath-Zwick, Mary Freeman, Lanier Jackson, Madison Johnson, Elizabeth Mack, Scott Pletzer, Natasha Ruth, Carolyn Taylor, Sinai Zyblewski, Katrina Golub, Chanel Rojas, Korsin Rosalind, Chantal Sanchez, Shubhika Srivastava, Carol Prospero, Ed Williams, Varsha Zadokar, Arash Sabati, Kylie Domian, Ashley Herzberg, Sanjana Khanna, Todd Nowlen, Susan Park, Jade Porche, Samantha Stack, Dongngan Truong, Andrea Dunn, Lilly Fagatele, Emma Joyce, Linda Lambert, Kirsten Dummer, Sherrie Bandy, Jane Burns, Katheryn Crane, Sanjeet Hedge, Joan Pancheri, Adriana Tremoulet, Ronald Mark Payne, Mary Stumpf, Michael Portman, Hidemi Kajimoto, Camden Hebson, Krissie Hock, Onyekachukwu Osakwe, Jemylle Morato, Divya Shakti, Matt Kadish, Kavita Sharma, William Anguiano, Catherine Ikemba, Alejandra Lozano, Maria Martinez, Wendy Rojas, Lerraughn Morgan, Isaura Macias, Carl Owada, Mayra Rangel, and Michelle Sykes

Subjects
PEDSnet, PCORnet, Long COVID, Chronic COVID-19 syndrome, Late sequelae of COVID-19, Long-haul COVID, Medicine (General), R5-920
Abstract

Summary: Background: Children from racial and ethnic minority groups are at greater risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether they have increased risk for post-acute sequelae of SARS-CoV-2 (PASC). Our objectives were to assess whether the risk of respiratory and neurologic PASC differs by race/ethnicity and social drivers of health. Methods: We conducted a retrospective cohort study of individuals

Published
2025
Full Text
View/download PDF

5. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants

Author

Panke Qu, Julia N. Faraone, John P. Evans, Yi-Min Zheng, Claire Carlin, Mirela Anghelina, Patrick Stevens, Soledad Fernandez, Daniel Jones, Ashish R. Panchal, Linda J. Saif, Eugene M. Oltz, Baoshan Zhang, Tongqing Zhou, Kai Xu, Richard J. Gumina, and Shan-Lu Liu

Subjects
CP: Microbiology, CP: Immunology, Biology (General), QH301-705.5
Abstract

Summary: Omicron subvariants continuingly challenge current vaccination strategies. Here, we demonstrate nearly complete escape of the XBB.1.5, CH.1.1, and CA.3.1 variants from neutralizing antibodies stimulated by three doses of mRNA vaccine or by BA.4/5 wave infection, but neutralization is rescued by a BA.5-containing bivalent booster. CH.1.1 and CA.3.1 show strong immune escape from monoclonal antibody S309. Additionally, XBB.1.5, CH.1.1, and CA.3.1 spike proteins exhibit increased fusogenicity and enhanced processing compared with BA.2. Homology modeling reveals the key roles of G252V and F486P in the neutralization resistance of XBB.1.5, with F486P also enhancing receptor binding. Further, K444T/M and L452R in CH.1.1 and CA.3.1 likely drive escape from class II neutralizing antibodies, whereas R346T and G339H mutations could confer the strong neutralization resistance of these two subvariants to S309-like antibodies. Overall, our results support the need for administration of the bivalent mRNA vaccine and continued surveillance of Omicron subvariants.

Published
2023
Full Text
View/download PDF

7. Power analysis for RNA-Seq differential expression studies using generalized linear mixed effects models

Author

Lianbo Yu, Soledad Fernandez, and Guy Brock

Subjects
RNA-Seq, Power analysis, Bivariate negative binomial, Generalized linear mixed effects Model, Computer applications to medicine. Medical informatics, R858-859.7, Biology (General), QH301-705.5
Abstract

Abstract Background Power analysis becomes an inevitable step in experimental design of current biomedical research. Complex designs allowing diverse correlation structures are commonly used in RNA-Seq experiments. However, the field currently lacks statistical methods to calculate sample size and estimate power for RNA-Seq differential expression studies using such designs. To fill the gap, simulation based methods have a great advantage by providing numerical solutions, since theoretical distributions of test statistics are typically unavailable for such designs. Results In this paper, we propose a novel simulation based procedure for power estimation of differential expression with the employment of generalized linear mixed effects models for correlated expression data. We also propose a new procedure for power estimation of differential expression with the use of a bivariate negative binomial distribution for paired designs. We compare the performance of both the likelihood ratio test and Wald test under a variety of simulation scenarios with the proposed procedures. The simulated distribution was used to estimate the null distribution of test statistics in order to achieve the desired false positive control and was compared to the asymptotic Chi-square distribution. In addition, we applied the procedure for paired designs to the TCGA breast cancer data set. Conclusions In summary, we provide a framework for power estimation of RNA-Seq differential expression under complex experimental designs. Simulation results demonstrate that both the proposed procedures properly control the false positive rate at the nominal level.

Published
2020
Full Text
View/download PDF

8. A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer

Author

Xiaoli Zhang, Brett Klamer, Jin Li, Soledad Fernandez, and Lang Li

Subjects
Class-3 semaphorins, Gene expression, Survival, Tumour suppressor or promoter, Immune subtype, Tumour microenvironment, Internal medicine, RC31-1245, Genetics, QH426-470
Abstract

Abstract Background Initially characterized as axon guidance factors, semaphorins also have been implicated to have critical roles in multiple physiological and developmental functions, including the regulation of immune responses, angiogenesis, organ formation, and the etiology of multiple forms of cancer. Moreover, their contribution in immunity and the regulation of tumour microenvironment is becoming increasingly recognized. Here, we provide a comprehensive analysis of class-3 semaphorins, the only secreted family of genes among veterbrate semaphorins, in terms of their expression profiles and their association with patient survival. We also relate their role with immune subtypes, tumour microenvironment, and drug sensitivity using a pan-cancer study. Results Expression profiles of class-3 semaphorins (SEMA3s) and their association with patient survival and tumour microenvironment were studied in 31 cancer types using the TCGA pan-cancer data. The expression of SEMA3 family varies in different cancer types with striking inter- and intra- cancer heterogeneity. In general, our results show that SEMA3A, SEMA3C, and SEMA3F are primarily upregulated in cancer cells, while the rest of SEMA3s are mainly down-regulated in the tested tumours. The expression of SEMA3 family members was frequently associated with patient overall survival. However, the direction of the association varied with regards to the particular SEMA3 isoform queried and the specific cancer type tested. More specifically, SEMA3A and SEMA3E primarily associate with a poor prognosis of survival, while SEMA3G typically associates with survival advantage. The rest of SEMA3s show either survival advantage or disadvantage dependent on cancer type. In addition, all SEMA3 genes show significant association with immune infiltrate subtypes, and they also correlate with level of stromal cell infiltration and tumour cell stemness with various degrees. Finally, our study revealed that SEMA3 genes, especially SEMA3C and SEMA3F may contribute to drug induced cancer cell resistance. Conclusions Our systematic analysis of class-3 semaphorin gene expression and their association with immune infiltrates, tumour microenvironment and cancer patient outcomes highlights the need to study each SEMA3 member as a separate entity within each specific cancer type. Also our study validated the identification of class-3 semaphorin signals as promising therapeutic targets in cancer although further laboratory validation still needed.

Published
2020
Full Text
View/download PDF

9. [18F] Sodium Fluoride Dose Reduction Enabled by Digital Photon Counting PET/CT for Evaluation of Osteoblastic Activity

Author

Maria I. Menendez, Richard R. Moore, Mahmoud Abdel-Rasoul, Chadwick L. Wright, Soledad Fernandez, Rebecca D. Jackson, and Michael V. Knopp

Subjects
[18F] sodium fluoride, PET/CT, digital photon counting, bone imaging, bone metabolism, sodium fluoride dose reduction, Medicine (General), R5-920
Abstract

The aim of the study was to assess the quality and reproducibility of reducing the injected [18F] sodium fluoride ([18F]NaF) dose while maintaining diagnostic imaging quality in bone imaging in a preclinical skeletal model using digital photon counting PET (dPET) detector technology. Beagles (n = 9) were administered three different [18F]NaF doses: 111 MBq (n = 5), 20 MBq (n = 5), and 1.9 MBq (n = 9). Imaging started ≃45 min post-injection for ≃30 min total acquisition time. Images were reconstructed using Time-of-Flight, ultra-high definition (voxel size of 1 × 1 × 1 mm3), with 3 iterations and 3 subsets. Point spread function was modeled and Gaussian filtering was applied. Skeleton qualitative and quantitative molecular image assessment was performed. The overall diagnostic quality of all images scored excellent (61%) and acceptable (39%) by all the reviewers. [18F]NaF SUVmean showed no statistically significant differences among the three doses in any of the region of interest assessed. This study demonstrated that a 60-fold [18F]NaF dose reduction was not significantly different from the highest dose, and it had not significant effect on overall image quality and quantitative accuracy. In the future, ultra-low dose [18F]NaF dPET/CT imaging may significantly decrease PET radiation exposure to preclinical subjects and personnel.

Published
2022
Full Text
View/download PDF

10. Fully moderated t-statistic in linear modeling of mixed effects for differential expression analysis

Author

Lianbo Yu, Jianying Zhang, Guy Brock, and Soledad Fernandez

Subjects
Fully moderated T-statistic, Linear mixed-effects model, Variance shrinkage, Expected number of false positives, Computer applications to medicine. Medical informatics, R858-859.7, Biology (General), QH301-705.5
Abstract

Abstract Background Gene expression profiling experiments with few replicates lead to great variability in the estimates of gene variances. Toward this end, several moderated t-test methods have been developed to reduce this variability and to increase power for testing differential expression. Most of these moderated methods are based on linear models with fixed effects where residual variances are smoothed under a hierarchical Bayes framework. However, they are inadequate for designs with complex correlation structures, therefore application of moderated methods to linear models with mixed effects are needed for differential expression analysis. Results We demonstrated the implementation of the fully moderated t-statistic method for linear models with mixed effects, where both residual variances and variance estimates of random effects are smoothed under a hierarchical Bayes framework. We compared the proposed method with two current moderated methods and show that the proposed method can control the expected number of false positives at the nominal level, while the two current moderated methods fail. Conclusions We proposed an approach for testing differential expression under complex correlation structures while providing variance shrinkage. The proposed method is able to improve power by moderation and controls the expected number of false positives properly at the nominal level.

Published
2019
Full Text
View/download PDF

11. Taraco Archaeological Project Report on 2003 Excavations at Kala Uyuni

Author

Bandy, Matthew, Hastorf, Christine A., Steadman, Lee, Moore, Katherine, Goodman Elgar, Melissa, Whitehead, William, Paz Soria, José Luis, Cohen, Amanda, Bruno, Maria, Roddick, Andrew, Frye, Kirk, Soledad Fernandez, Maria, Capriles Flores, José, and Leighton, Mary

Subjects
Archaeological Anthropology, archaeology, anthropology, ritual, mound, botany, archaeobotany, faunal remains, microstratigraphy, ethnoarchaeology, bolivia, andes, latin america, south america
Published
2004

12. Proyecto Arqueológico Taraco Informe de la Temporada de Campo 2003: Excavaciones en Kala Uyuni

Author

Bandy, Matthew, Hastorf, Christine A., Steadman, Lee, Moore, Katherine, Goodman Elgar, Melissa, Whitehead, William, Paz Soria, José Luis, Cohen, Amanda, Bruno, Maria, Roddick, Andrew, Frye, Kirk, Soledad Fernandez, Maria, Capriles Flores, José, and Leighton, Mary

Subjects
Archaeological Anthropology, arqueología, anthropología, rituales, botanía, arqueobotanía, microstratígrafía, ethnoarchaeologia, bolivia, andes, latino america, america sur
Published
2004

13. Power analysis for RNA-Seq differential expression studies

Author

Lianbo Yu, Soledad Fernandez, and Guy Brock

Subjects
RNA-Seq, Power, Wald test, Likelihood ratio test, Computer applications to medicine. Medical informatics, R858-859.7, Biology (General), QH301-705.5
Abstract

Abstract Background Sample size calculation and power estimation are essential components of experimental designs in biomedical research. It is very challenging to estimate power for RNA-Seq differential expression under complex experimental designs. Moreover, the dependency among genes should be taken into account in order to obtain accurate results. Results In this paper, we propose a simulation based procedure for power estimation using the negative binomial distribution and assuming a generalized linear model (at the gene level) that considers the dependence between gene expression level and its variance (dispersion) and also allows equal or unequal dispersion across conditions. We compared the performance of both Wald test and likelihood ratio test under different scenarios. The null distribution of the test statistics was simulated for the desired false positive control to avoid excess false positives with the usage of an asymptotic chi-square distribution. We applied this method to the TCGA breast cancer data set. Conclusions We provide a framework for power estimation of RNA-Seq data. The proposed procedure is able to properly control the false positive error rate at the nominal level.

Published
2017
Full Text
View/download PDF

16. La escuela con Jornada Extendida rionegrina: expresiones político - pedagógicas de un proyecto focalizado y localizado

Author

María Soledad Fernandez

Subjects
Estado, Familias, Escuela, Jornada extendida, Education (General), L7-991, Anthropology, GN1-890
Abstract

La experiencia que aquí presento se propone describir las relaciones entre escuela y familias en instituciones primarias con jornada extendida insertas en contextos de pobreza urbana en la provincia de Río Negro tomando como eje de análisis las prácticas situadas que convierten una política focalizada en un proyecto político localizado. El programa de "Escuelas de Jornada Extendida" es considerado en esta investigación etnográfica como una política educativa focalizada. En este sentido, al encarnarse en prácticas concretas de las personas, se reconfiguran sus sentidos en prácticas localizadas, interpeladas por disputas de acentos en torno a que es y que se espera de la extensión del tiempo escolar tanto para los trabajadores de la escuela como para las familias de los niños. El enfoque de investigación con el que realicé este trabajo es el etnográfico. En este marco epistemológico y metodológico, hacer etnografía respondió al propósito de describir los fenómenos sociales observados acompañando continuamente la acción de "observar participando" con un trabajo reflexivo sobre el mismo proceso de investigación, con el fin de refinar o construir categorías teóricas que orienten la descripción y comprensión de los fenómenos estudiados.

Published
2018

18. Supplemental Table 1 from Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy

Author

Peter J. Houghton, Xiaokui Mo, Soledad Fernandez, Robert E. Hollingsworth, Haihong Zhong, Jin Gao, Cheryl A. London, and Hemant K. Bid

Abstract

Supplemental Table 1 PDF file 56K, Comparisons of time-to-event curves for single or combined antibody therapy against pediatric sarcoma xenografts (listed are adjusted p-values)

Published
2023
Full Text
View/download PDF

19. Supplementary Table 1, Figures 1 - 3 from Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma

Author

Peter J. Houghton, Soledad Fernandez, Xiaokui Mo, Raushan T. Kurmasheva, Paul D. Smith, Mariko DeWire, Brian Geier, Duane Oswald, David Capper, Jiayuh Lin, Linlin Xiao, Sagymbek Manap, Doris A. Phelps, Aaron Kibler, and Hemant K. Bid

Abstract

PDF file - 9027K, Supplemental Table 1 and supplemental Figures 1-3 Supplemental Table 1. MEK functional activation gene signature qRT-PCR results Supplemental Figure 1. For individual growth curve plots: Upper left panel: Control; Upper right panel: AZD6244 100 mg/kg BID x 5/SID x 2 for six consecutive weeks; lower left panel: AZD6244 75 mg/kg BID x 5/SID x 2 for six consecutive weeks; Lower right panel100 mg/kg SID for six consecutive weeks. Tumors A5 and B4 (arrowed) were selected for further transplant to select for selumetinib resistance in vivo. Supplemental Figure 2. Representative immunostaining of BT-40 and derivative xenografts using the VE1 antibody that recognizes BRAFV600E.Tumor samples were fixed and stained as described in a Materials and Methods and read 'blinded' (DC). Panels at the bottom were stained simultaneously and demonstrate intensity of staining for patient derived brain tumors. Supplemental Figure 3. qRT-�PCR to detect IL6 receptor alpha was performed using human-specific primers on snap-�frozen control tumor tissue as described in Supplemental Table 1.

Published
2023
Full Text
View/download PDF

22. Supplementary Data from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

Author

Hiroshi Nakashima, E. Antonio Chiocca, Gordon J. Freeman, David A. Reardon, Soledad Fernandez, Eric McLaughlin, William Goins, Maria C. Speranza, Khalid Shah, Sean E. Lawler, Marco Mineo, Vivek Bhaskaran, Hirotaka Ito, Korneel Grauwet, John McNulty, Isabel DeLaura, Quazim Alayo, and Carmela Passaro

Abstract

Supplementary figure legends

Published
2023
Full Text
View/download PDF

23. Data from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

Author

Hiroshi Nakashima, E. Antonio Chiocca, Gordon J. Freeman, David A. Reardon, Soledad Fernandez, Eric McLaughlin, William Goins, Maria C. Speranza, Khalid Shah, Sean E. Lawler, Marco Mineo, Vivek Bhaskaran, Hirotaka Ito, Korneel Grauwet, John McNulty, Isabel DeLaura, Quazim Alayo, and Carmela Passaro

Abstract

Purpose:Glioblastoma (GBM) is resistant to standard of care. Immune checkpoints inhibitors (such as anti-PD-1 mAbs) efficiently restore antitumor T-cell activity. We engineered a new oncolytic herpes simplex virus (oHSV) expressing a single-chain antibody against PD-1 (scFvPD-1) to evaluate its efficacy in mouse models of GBM.Experimental Design:NG34scFvPD-1 expresses the human GADD34 gene transcriptionally controlled by the Nestin promoter to allow replication in GBM cells and a scFvPD-1 cDNA transcriptionally controlled by the CMV promoter. ELISA assays were performed to detect binding of scFvPD-1 to mouse and human PD-1. In vitro cytotoxicity and replication assays were performed to measure NG34scFvPD-1 oncolysis, and scFvPD-1 expression and secretion were determined. In vivo survival studies using orthotopic mouse GBM models were performed to evaluate the therapeutic potency of NG34scFvPD-1.Results:NG34scFvPD-1–infected GBM cells express and secrete scFvPD-1 that binds mouse PD-1. The introduction of the scFvPD-1 sequence in the viral backbone does not alter the oncolytic properties of NG34scFvPD-1. In situ NG34scFvPD-1 treatment improved the survival with a tail of durable survivorship in 2 syngeneic immunocompetent mouse models of GBM. Mice that survived the first GBM challenge rejected the second challenge of GBM when implanted in the contralateral hemisphere. However, this was not true when athymic mice were employed as the recipients of the second challenge, consistent with the need for an intact immune system to obtain a memory response.Conclusions:NG34scFvPD-1 treatment induces a durable antitumor response in 2 preclinical mouse models of GBM with evidence for antitumor memory.

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 2 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

Author

Hiroshi Nakashima, E. Antonio Chiocca, Gordon J. Freeman, David A. Reardon, Soledad Fernandez, Eric McLaughlin, William Goins, Maria C. Speranza, Khalid Shah, Sean E. Lawler, Marco Mineo, Vivek Bhaskaran, Hirotaka Ito, Korneel Grauwet, John McNulty, Isabel DeLaura, Quazim Alayo, and Carmela Passaro

Abstract

Engineering of NG34 to insert the sequence of the scFv against PD-1

Published
2023
Full Text
View/download PDF

25. Data from Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy

Author

Peter J. Houghton, Xiaokui Mo, Soledad Fernandez, Robert E. Hollingsworth, Haihong Zhong, Jin Gao, Cheryl A. London, and Hemant K. Bid

Abstract

Background: In pediatric tumor xenograft models, tumor-derived insulin growth factor (IGF-2) results in intrinsic resistance to IGF-IR–targeted antibodies, maintaining continued tumor angiogenesis. We evaluated the antiangiogenic activity of a ligand-binding antibody (MEDI-573) alone or in combination with IGF-I receptor binding antibodies (MAB391, CP01-B02).Methods: IGF-stimulated signaling was monitored by increased Akt phosphorylation in sarcoma and human umbilical cord vascular endothelial cells (HUVEC). Angiogenesis was determined in vitro using capillary tube formation in HUVECs and in vivo using a VEGF-stimulated Matrigel assay. Tumor growth delay was examined in 4 sarcoma xenograft models.Results: The IGF ligand-binding antibody MEDI-573 suppressed Akt phosphorylation induced by exogenous IGF-I and IGF-2 in sarcoma cells. Receptor-binding antibodies suppressed IGF-I stimulation of Akt phosphorylation, but IGF-2 circumvented this effect and maintained HUVEC tube formation. MEDI-573 inhibited HUVEC proliferation and tube formation in vitro, but did not inhibit angiogenesis in vivo, probably because MEDI-573 binds murine IGF-I with low affinity. However, in vitro antiangiogenic activity of MEDI-573 was also circumvented by human recombinant IGF-I. The combination of receptor- and ligand-binding antibodies completely suppressed VEGF-stimulated proliferation of HUVECs in the presence of IGF-I and IGF-2, prevented ligand-induced phosphorylation of IGF-IR/IR receptors, and suppressed VEGF/IGF-2–driven angiogenesis in vivo. The combination of CP1-BO2 plus MEDI-573 was significantly superior to therapy with either antibody alone against IGF-I and IGF-2 secreting pediatric sarcoma xenograft models.Conclusions: These results suggest that combination of antibodies targeting IGF receptor and ligands may be an effective therapeutic strategy to block angiogenesis for IGF-driven tumors. Clin Cancer Res; 19(11); 2984–94. ©2013 AACR.

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 1 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

Author

Hiroshi Nakashima, E. Antonio Chiocca, Gordon J. Freeman, David A. Reardon, Soledad Fernandez, Eric McLaughlin, William Goins, Maria C. Speranza, Khalid Shah, Sean E. Lawler, Marco Mineo, Vivek Bhaskaran, Hirotaka Ito, Korneel Grauwet, John McNulty, Isabel DeLaura, Quazim Alayo, and Carmela Passaro

Abstract

Purification of the scFvPD-1 from HEK293 cells

Published
2023
Full Text
View/download PDF

31. Data from Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma

Author

Peter J. Houghton, Soledad Fernandez, Xiaokui Mo, Raushan T. Kurmasheva, Paul D. Smith, Mariko DeWire, Brian Geier, Duane Oswald, David Capper, Jiayuh Lin, Linlin Xiao, Sagymbek Manap, Doris A. Phelps, Aaron Kibler, and Hemant K. Bid

Abstract

Purpose: The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAFV600E and is highly sensitive to the MEK inhibitor selumetinib (AZD6244). In this study, we developed and characterized selumetinib resistance and explored approaches to circumventing the mechanisms of acquired resistance.Experimental Design: BT-40 xenografts were selected in vivo for selumetinib resistance. Resistant tumors were obtained and characterized, as were tumors that reverted to sensitivity. Characterization included expression profiling, assessment of MEK signature and compensatory pathways, MEK inhibition, BRAF expression, and cytokine levels. Combination treatment of BT-40/AZD–resistant tumors with the MEK inhibitor and a STAT3 inhibitor (LLL12) was assessed.Results: Resistance was unstable, tumors reverting to selumetinib sensitivity when passaged in untreated mice, and MEK was equally inhibited in sensitive and resistant tumors by selumetinib. Drug resistance was associated with an enhanced MEK signature and increased interleukin (IL)-6 and IL-8 expression. Selumetinib treatment induced phosphorylation of STAT3 (Y705) only in resistant xenografts, and similar results were observed in BRAFV600E astrocytic cell lines intrinsically resistant to selumetinib. Treatment of BT-40–resistant tumors with selumetinib or LLL12 had no significant effect, whereas combined treatment induced complete regressions of BT-40/AZD–resistant xenografts.Conclusions: Resistance to selumetinib selected in vivo in BT-40 tumor xenografts was unstable. In resistant tumors, selumetinib activated STAT3, and combined treatment with selumetinib and LLL12 induced complete responses in resistant BT-40 tumors. These results suggest dual targeting BRAF (V600E) signaling and STAT3 signaling may be effective in selumetinib-resistant tumors or may retard or prevent onset of resistance. Clin Cancer Res; 19(24); 6716–29. ©2013 AACR.

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 3 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

Author

Hiroshi Nakashima, E. Antonio Chiocca, Gordon J. Freeman, David A. Reardon, Soledad Fernandez, Eric McLaughlin, William Goins, Maria C. Speranza, Khalid Shah, Sean E. Lawler, Marco Mineo, Vivek Bhaskaran, Hirotaka Ito, Korneel Grauwet, John McNulty, Isabel DeLaura, Quazim Alayo, and Carmela Passaro

Abstract

In vivo comparison of scFvPD-1 production and viral gene expression in mouse and human GBM cells

Published
2023
Full Text
View/download PDF

33. Data from DNA Demethylating Agents Synergize with Oncolytic HSV1 against Malignant Gliomas

Author

E. Antonio Chiocca, Balveen Kaur, Soledad Fernandez, Amy Lehman, Allison Wehr, Xiaokui Mo, Chelsea Bolyard, Hans Meisen, Amy Haseley, Benjamin Wagner, Kazue Kasai, and Kazuo Okemoto

Abstract

Purpose: Oncolytic viruses (OV) based on herpes simplex virus type 1 (HSV1) are being used in clinical trials for a variety of cancers. The OV, rQNestin34.5, uses a nestin promoter/enhancer to selectively drive robust viral replication in malignant glioma cells. We have discovered that this promoter becomes extensively methylated in infected glioma cells, reducing OV efficacy.Experimental Design: We used demethylating drugs [5-azacytidine (5-Aza)], decitabine, or valproic acid (VPA) in both in vitro and in vivo malignant glioma models to determine if they improved the efficacy of rQNestin34.5 therapy.Results: The use of demethylating agents, such as 5-Aza, improved OV replication and tumor cell lysis in vitro and, in fact, synergized pharmacologically on Chou–Talalay analysis. In vivo, the combination of the demethylating agents, 5-Aza or decitabine, with rQNestin34.5 significantly prolonged the survivorship of athymic mice harboring intracranial human glioma xenografts over single agent alone.Conclusion: These results, thus, provide further justification for the exploration of demethylating agents when combined with the OV, rQNestin34.5, in preclinical therapeutics and, possibly, clinical trials for malignant glioma. Clin Cancer Res; 19(21); 5952–9. ©2013 AACR.

Published
2023
Full Text
View/download PDF

34. Supplementary Movie 1 from An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis

Author

Michael C. Ostrowski, Gustavo Leone, Kun Huang, Soledad Fernandez, Thomas J. Rosol, Ruchika Srinivasan, Brett Adair, Anand Merchant, Sudarshana M. Sharma, David A. Taffany, and Tahera Zabuawala

Abstract

Supplementary Movie 1 from An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis

Published
2023
Full Text
View/download PDF

35. Supplementary Movie 3 from An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis

Author

Michael C. Ostrowski, Gustavo Leone, Kun Huang, Soledad Fernandez, Thomas J. Rosol, Ruchika Srinivasan, Brett Adair, Anand Merchant, Sudarshana M. Sharma, David A. Taffany, and Tahera Zabuawala

Abstract

Supplementary Movie 3 from An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis

Published
2023
Full Text
View/download PDF

36. Supplementary Figure and Movie Legends from An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis

Author

Michael C. Ostrowski, Gustavo Leone, Kun Huang, Soledad Fernandez, Thomas J. Rosol, Ruchika Srinivasan, Brett Adair, Anand Merchant, Sudarshana M. Sharma, David A. Taffany, and Tahera Zabuawala

Abstract

Supplementary Figure and Movie Legends from An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis

Published
2023
Full Text
View/download PDF

37. Supplementary Figures 1-7 from An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis

Author

Michael C. Ostrowski, Gustavo Leone, Kun Huang, Soledad Fernandez, Thomas J. Rosol, Ruchika Srinivasan, Brett Adair, Anand Merchant, Sudarshana M. Sharma, David A. Taffany, and Tahera Zabuawala

Abstract

Supplementary Figures 1-7 from An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis

Published
2023
Full Text
View/download PDF

40. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2

Author

Panke Qu, John P. Evans, Julia N. Faraone, Yi-Min Zheng, Claire Carlin, Mirela Anghelina, Patrick Stevens, Soledad Fernandez, Daniel Jones, Gerard Lozanski, Ashish Panchal, Linda J. Saif, Eugene M. Oltz, Kai Xu, Richard J. Gumina, and Shan-Lu Liu

Subjects
Virology, Parasitology, Microbiology
Abstract

The continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron subvariants, including BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Here, we examine the neutralization resistance of these subvariants against sera from 3-dose vaccinated healthcare workers, hospitalized BA.1-wave patients, and BA.4/5-wave patients. We found enhanced neutralization resistance in all new subvariants, especially in the BQ.1 and BQ.1.1 subvariants driven by N460K and K444T mutations, as well as the BA.2.75.2 subvariant driven largely by its F486S mutation. All Omicron subvariants maintained their weakened infectivity in Calu-3 cells, with the F486S mutation driving further diminished titer for the BA.2.75.2 subvariant. Molecular modeling revealed the mechanisms of antibody-mediated immune evasion by R346T, K444T, F486S, and D1199N mutations. Altogether, these findings shed light on the evolution of newly emerging SARS-CoV-2 Omicron subvariants.

Published
2022

41. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2

Author

Panke Qu, John P. Evans, Julia Faraone, Yi-Min Zheng, Claire Carlin, Mirela Anghelina, Patrick Stevens, Soledad Fernandez, Daniel Jones, Gerard Lozanski, Ashish Panchal, Linda J. Saif, Eugene M. Oltz, Kai Xu, Richard J. Gumina, and Shan-Lu Liu

Abstract

Continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron subvariants, including BQ.1, BQ. 1.1, BA.4.6, BF.7 and BA.2.75.2. Here we examine the neutralization resistance of these subvariants, as well as their ancestral BA.4/5, BA.2.75 and D614G variants, against sera from 3-dose vaccinated health care workers, hospitalized BA.1-wave patients, and BA.5-wave patients. We found enhanced neutralization resistance in all new subvariants, especially the BQ.1 and BQ.1.1 subvariants driven by a key N460K mutation, and to a lesser extent, R346T and K444T mutations, as well as the BA.2.75.2 subvariant driven largely by its F486S mutation. The BQ.1 and BQ.1.1 subvariants also exhibited enhanced fusogenicity and S processing dictated by the N460K mutation. Interestingly, the BA.2.75.2 subvariant saw an enhancement by the F486S mutation and a reduction by the D1199N mutation to its fusogenicity and S processing, resulting in minimal overall change. Molecular modelling revealed the mechanisms of receptor-binding and non-receptor binding monoclonal antibody-mediated immune evasion by R346T, K444T, F486S and D1199N mutations. Altogether, these findings shed light on the concerning evolution of newly emerging SARS-CoV-2 Omicron subvariants.

Published
2022
Full Text
View/download PDF

42. Assessment of Fall-Related Emergency Medical Service Calls and Transports after a Community-Level Fall-Prevention Initiative

Author

Carmen E. Quatman, Elizabeth Sheridan, Mark Weade, David H. Wisner, Ashish R. Panchal, Jennifer H. Garvin, Mindy Gabriel, Soledad Fernandez, Jessica Wiseman, John F.P. Bridges, Heena P. Santry, and Catherine Quatman-Yates

Subjects
Relative risk reduction, Emergency Medical Services, medicine.medical_specialty, Quality management, Chronic care management, Allied Health Personnel, 030204 cardiovascular system & hematology, Emergency Nursing, Article, 03 medical and health sciences, 0302 clinical medicine, Clinical pathway, Injury prevention, Humans, Medicine, business.industry, Public health, 030208 emergency & critical care medicine, Paramedicine, medicine.disease, United States, Emergency Medical Technicians, Emergency Medicine, Medical emergency, people, business, people.professional_field, Fall prevention
Abstract

BACKGROUND: Getting effective fall prevention into the homes of medically and physically vulnerable individuals is a critical public health challenge. Community paramedicine is emerging globally as a new model of care that allows emergency medical service units to evaluate and treat patients in non-emergency contexts for prevention efforts and chronic care management. The promise of community paramedicine as a delivery system for fall prevention that scales to community-level improvements in outcomes is compelling but untested. OBJECTIVE: To study the impact of a community paramedic program’s optimization of a fall prevention system entailing a clinical pathway and learning health system (called Community-FIT) on community-level fall-related emergency medical service utilization rates. METHODS: We used an implementation science framework and quality improvement methods to design and optimize a fall prevention model of care that can be embedded within community paramedic operations. The model was implemented and optimized in an emergency medical service agency servicing a Midwestern city in the United States (~35,000 residents). Primary outcome measures included relative risk reduction in the number of community-level fall-related 9-1-1 calls and fall-related hospital transports. Interrupted time series analysis was used to evaluate relative risk reduction from a 12-month baseline period (September 2016 - August 2017) to a 12-month post-implementation period (September 2018 – August 2019). RESULTS: Community paramedic home visits increased from 25 in 2017, to 236 in 2018, to 517 in 2019, indicating a large increase in the number of households that benefitted from the efforts. A relative risk reduction of 0.66 (95% [CI] 0.53, 0.76) in the number of fall calls and 0.63 (95% [CI] 0.46, 0.75) in the number of fall-related calls resulting in transports to the hospital were observed. CONCLUSIONS: Community-FIT may offer a powerful mechanism for community paramedics to reduce fall-related 9-1-1 calls and transports to hospitals that can be implemented in emergency medical agencies across the country.

Published
2021
Full Text
View/download PDF

43. Cartografías del conflicto ambiental en Argentina II

Author

Merlinsky, Gabriela, compiladora, Astelarra, Sofía, Beltramino, Tamara, Fernández, Leonardo, Bouzo, Soledad Fernández, Langbehn, Lorenzo, Larsimont, Robin, Martín, Facundo, Montera, Carolina, Ramírez, Delia, Scharager, Andrés, Schmidt, Mariana, Tobías, Melina, López, Virginia Toledo, Merlinsky, Gabriela, Astelarra, Sofía, Beltramino, Tamara, Fernández, Leonardo, Bouzo, Soledad Fernández, Langbehn, Lorenzo, Larsimont, Robin, Martín, Facundo, Montera, Carolina, Ramírez, Delia, Scharager, Andrés, Schmidt, Mariana, Tobías, Melina, and López, Virginia Toledo

Published
2019
Full Text
View/download PDF

44. Las ciencias sociales en tiempos de ajuste : Artículos seleccionados de las IX Jornadas de Jóvenes Investigadores del Instituto de Investigaciones Gino Germani

Author

Neer, Anahí Farji, González, Anahí, Greco, Mauro, Le Borgne de Boisriou, Valentine, Unzué, Martín, Prólogo, Sustas, Sebastián E., Riveiro, Manuel, Krause, Mercedes, Bouzo, Soledad Fernández, Nardín, Santiago, Trovero, Juan I., Wassmansdorf, Marina Lis, Goldentul, Analía, Galimberti, Carlos, Mutuverría, Marcos, Colman, Alex, Lascurain, María Cecilia, Tóffoli, María Magdalena, Vieites, Andrea, Fuentes, Sebastián, Stramucci, Luis Emilio, Barreto, Lucas, Berardo, Martina Daniela, Vázquez, Diego Ezequiel, Alvira, Paula Soledad, Romero, Francisco Fernández, Neer, Anahí Farji, González, Anahí, Greco, Mauro, Le Borgne de Boisriou, Valentine, Unzué, Martín, Sustas, Sebastián E., Riveiro, Manuel, Krause, Mercedes, Bouzo, Soledad Fernández, Nardín, Santiago, Trovero, Juan I., Wassmansdorf, Marina Lis, Goldentul, Analía, Galimberti, Carlos, Mutuverría, Marcos, Colman, Alex, Lascurain, María Cecilia, Tóffoli, María Magdalena, Vieites, Andrea, Fuentes, Sebastián, Stramucci, Luis Emilio, Barreto, Lucas, Berardo, Martina Daniela, Vázquez, Diego Ezequiel, Alvira, Paula Soledad, and Romero, Francisco Fernández

Published
2019
Full Text
View/download PDF

46. Spatial and temporal changes in Lutzomyia longipalpis abundance, a Leishmania infantum vector in an urban area in northeastern Argentina

Author

Maria Soledad Fernandez, Maria Soledad Santini, Regino Cavia, Adolfo Enrique Sandoval, Adriana Alicia Perez, Soraya Acardi, and Oscar Daniel Salomon

Subjects
Lutzomyia longipalpis, visceral leishmaniasis, urban environment, Microbiology, QR1-502, Infectious and parasitic diseases, RC109-216
Abstract

This study aimed to analyse changes in the spatial distribution of Lutzomyia longipalpis in Posadas, an urban area located in northeastern Argentina. Data were obtained during the summer of 2007 and 2009 through two entomological surveys of peridomiciles distributed around the city. The abundance distribution pattern for 2009 was computed and compared with the previous pattern obtained in 2007, when the first human visceral leishmaniasis cases were reported in the city. Vector abundance was also examined in relation to micro and macrohabitat characteristics. In 2007 and 2009, Lu. longipalpis was distributed among 41.5% and 31% of the households in the study area, respectively. In both years, the abundance rates at most of the trapping sites were below 30 Lu. longipalpis per trap per night; however, for areas exhibiting 30-60 Lu. longipalpis and more than 60 Lu. longipalpis, the areas increased in both size and number from 2007-2009. Lu. longipalpis was more abundant in areas with a higher tree and bush cover (a macrohabitat characteristic) and in peridomiciles with accumulated unused material (a microhabitat characteristic). These results will help to prioritise and focus control efforts by defining which peridomiciles display a potentially high abundance of Lu. longipalpis.

Published
2013
Full Text
View/download PDF

47. SPATIAL DISTRIBUTION OF PHLEBOTOMINAE IN PUERTO IGUAZU-MISIONES, ARGENTINA-BRAZIL-PARAGUAY BORDER AREA

Author

Maria Soledad Santini, Ignacio Tomas Gould, Mariana Manteca Acosta, Pablo Berrozpe, Soraya Alejandra Acardi, Maria Soledad Fernandez, Andrea Gomez, and Oscar Daniel Salomon

Subjects
Phlebotominae fauna, Leishmaniasis, Argentina-Brazil-Paraguay, Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216
Abstract

SUMMARY The first Argentinian autochthonous human case of visceral leishmaniasis (VL) was confirmed in Posadas (Misiones) in 2006. Since then, the disease has increased its incidence and geographical distribution. In the 2006-2012 period, 107 human cases were detected (11 deaths). The presence of Lutzomyia longipalpis was detected in peridomiciles in Puerto Iguazú urban area in 2010; some of these findings were associated with households where cases of canine VL had already been reported. The objective of this study was to ascertain the abundance and spatial distribution of Lu. longipalpis in Puerto Iguazú City, on the Argentina-Brazil-Paraguay border. Lu. longipalpis proved to be exclusively urban and was found in 31% of the households sampled (n = 53), 67% of which belonged to areas of low abundance, 20% to areas of moderate abundance and 13% to areas of high abundance. Nyssomyia whitmani was the only species found both in urban and peri-urban environments, and Migonemyia migonei was registered only on the outskirts of the city. Due to the fact that Puerto Iguazú is considered to be at moderate risk at the moment, it is necessary to intensify human and canine case controls, as well as take integrated prevention and control measures regarding the environment, vectors and reservoirs on the Argentina-Brazil-Paraguay border area.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results